88301-98-8

Basic information

• Product Name: 2-Methyl-6-(trifluoromethyl)aniline
• Synonyms: BenzenaMine,2-Methyl-6-(trifluoroMethyl)-;2-Amino-3-methylbenzotrifluoride
• CAS NO: 88301-98-8
• Molecular Formula: C₈H₈F₃N
• Molecular Weight: 175.15
• Mol File: 88301-98-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 198.831 °C at 760 mmHg
• Flash Point: 81.588 °C
• Appearance: /
• Density: 1.238 g/cm³
• Vapor Pressure: 0.352mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• PKA: 1.32±0.10(Predicted)
• CAS DataBase Reference: 2-Methyl-6-(trifluoromethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-6-(trifluoromethyl)aniline(88301-98-8)
• EPA Substance Registry System: 2-Methyl-6-(trifluoromethyl)aniline(88301-98-8)

Safety Data

• Hazardous Substances Data: 88301-98-8(Hazardous Substances Data)

Usage

General Description

2-Methyl-6-(trifluoromethyl)aniline is a chemical compound with the molecular formula C9H10F3N. It is an aromatic amine with a methyl group and a trifluoromethyl group attached to the benzene ring. 2-Methyl-6-(trifluoromethyl)aniline is often used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a dye intermediate and in the production of other organic compounds. 2-Methyl-6-(trifluoromethyl)aniline is a toxic and potentially hazardous chemical, and proper safety precautions should be taken when handling and working with it.

InChI:InChI=1/C8H8F3N/c1-5-3-2-4-6(7(5)12)8(9,10)11/h2-4H,12H2,1H3

Upstream product

• 92891-23-1 2-nitro-3-trifluoromethyl-toluene 
• 88301-74-0 2-(Chloromethyl)-6-(trifluoromethyl)anilinium Chloride 
• 88301-97-7 <2-Amino-3-(trifluoromethyl)benzyl>trimethylammonoium chloride 
• 75-63-8 Bromotrifluoromethane 
• 95-53-4 o-toluidine 
• 401-79-6 1-methyl-3-trifluoromethyl-benzene 
• 88301-96-6 2-{(methylthio)methyl}-6-(trifluoromethyl)aniline 
• 88301-75-1 2-(methylsulfinylmethyl)-6-(trifluoromethyl)-aniline 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 
• 1752-87-0 N-o-tolyl-2-pyridinecarboxamide 
• 67-56-1 methanol 
• 88798-15-6 N-(2-trifluoromethylphenyl)-S,S-dimethyl sulfilimine 

Downstream Products

• 864539-96-8 4-bromo-2-methyl-6-(trifluoromethyl)aniline 
• 1374258-43-1 5-bromo-7-(trifluoromethyl)-1H-indazole 
• 1374258-44-2 methyl 7-(trifluoromethyl)-1H-indazole-5-carboxylate 
• 910575-82-5 3-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-2-oxo-propionic acid 
• 910575-84-7 (R)-3-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-2-hydroxy-propionic acid methyl ester 
• 910575-83-6 (R)-3-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-2-hydroxy-propionic acid 
• 910575-81-4 (Z,E)-2-acetylamino-3-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-acrylic acid methyl ester 
• 910575-85-8 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910575-86-9 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-amino-3-methyl-5-trifluoromethyl-phenyl)-1-carboxy-ethyl ester 

Relevant articles and documents

Synthesis, sciatic nerve block activity evaluation and molecular docking of fluoro-substituted lidocaine analogs as local anesthetic agents

Thirty fluoro-substituted lidocaine analogs (10a–e, 11a–e, 14a–e, 15a–e, 18a–e and 19a–e) were synthesized, and their sciatic nerve block activity were evaluated as local anesthesia. Most of the compounds displayed significant potency, and compound 10a in particular was much more potent than the parent lidocaine. Fifteen analogs including 10a demonstrated pKa values of 7.5–7.8 suitable for local anesthesia. Compound 10a, 14e, and lidocaine were docked into three target receptors of local anesthetics by molecular docking studies to delineate structure-activity relationships and explain the differences in activities. Hydrophobic interactions and hydrogen bonds were identified key to molecular binding, suggesting that optimization of these interactions and/or trifluoro-substitution at the benzene ring of lidocaine could enhance the properties of lidocine analogs for local anesthesia.

CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I) in which: R1, R2, R3, R4 and X are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts as well as the hydrates of the salts, in particular, their physiologically compatible salts with inorganic or organic acids and bases, and those compounds of general formula (I) in which one or more hydrogen atoms are replaced by deuterium. The invention also relates to medicaments containing these compounds, the use thereof, and to methods for producing them.

Reactions of Trifluoromethyl Bromide and Related Halides: Part 10. Perfluoroalkylation of Aromatic Compounds induced by Sulphur Dioxide Radical Anion Precursors

Perfluoroalkylation of electron-rich aromatic compounds with trifluoromethyl bromide, or long-chain perfluoroalkyl iodides, was performed in the presence of sodium dithionite or zinc-sulphur dioxide.This alkylation occurred at the ortho and para positions relative to the amino or hydroxy substitutent.Pyrroles were perfluoroalkylated regioselectively at the 2-position.This alkylation was interpreted as a radical aromatic substitution; the formation of the perfluoroalkyl radical can be induced by a single-electron transfer from sulphur dioxide radical anion to the perfluoroalkyl halide.